858 Therapeutics Is A Clinical Stage Biotechnology Company Based In San Diegocaliforniafounded In 2019The Company Focuses On Discovering And Developing Small Molecule Therapeutics That Target Novel Pathways In Oncology And Immunologythe Leadership Team Has Extensive Experience In Biotech Innovationhaving Previously Led Drug Discovery Efforts At Several Successful Companies The Company S Therapeutic Portfolio Includes Programs Targeting Dna Damage Repairrna Epigeneticsand Innate Immunitytheir Lead Program Is A Parg Inhibitor Currently In Early Clinical Development For Oncology858 Therapeutics Has Raised $60 Million In Series A Financing And Collaborates With Partners Like Openbench To Enhance Drug Discovery Through Ai Driven Approachesthe Company Emphasizes Target Discovery And Translational Research To Advance Its Programs From Preclinical Stages To Clinical Trials
